Chugai files of Japanese approval of Avastin for ovarian cancer

11 October 2012

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority-owned by Swiss drug major Roche (ROG: SIX) says that it filed an application with the Japanese Ministry of Health, Labor and Welfare (MHLW) for the approval of an additional indication of ovarian cancer (including primary peritoneal cancer and fallopian tube cancer) for the anti-cancer agent/ anti-VEGF humanized monoclonal antibody, Avastin (bevacizumab (recombinant) for Infusion]).

Chugai said that, on December 13, 2010, it received a request from the MHLW to develop Avastin for the treatment of ovarian cancer, as a result of the evaluation by the Review Committee on Unapproved Drugs and Indications with High Medical Needs, and has been preparing to file for the addition of this indication.

Just last month, also at the request of the MHLW, Chugai filed an application with the regulator for the approval of an additional indication of recurrent glioblastoma for Avastin (The Pharma Letter September 21).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK